209 words; Main text, 2083 words, 6 figures, 1 table Abstract (209 words)
Introduction
Platelets are essential for hemostasis and thrombosis, and also play important roles in wound repair, inflammatory reactions, angiogenesis, lymph-vessel separation, and tumor metastasis (1) . In humans, approximately 1x10 11 platelets are produced each day, presumably through the cytoplasmic fragmentation of megakaryocytes (MKs) and/or formation of proplatelets, elongated pseudopods that extend from mature MKs and release platelets (2) .
Platelets production requires the commitment of hematopoietic stem cells (HSCs)/hematopoietic progenitor cells (HPCs) to the MK lineage, followed by proliferation of the progenitors and terminal differentiation. Ultimately, immature MKs develop a unique membrane complex called the demarcation membrane (DM) system, which is thought to serve as a membrane reservoir for platelet biogenesis through both direct cytoplasmic rupture and elongation of proplatelets (3) . Both of those processes are controlled by the orchestrated activities of numerous signaling molecules (3) . A variety of gene-targeted mouse models have shed light on the roles played by the transcriptional factors involved in platelet formation, and have contributed to the characterization of the linkage between the machinery of MK maturation and platelet release (3, 4, 5, 6, 7) . However, the actual machinery of platelet release (platelet biogenesis) from MKs has not yet been characterized (8) .
The establishment of mouse (9) and human embryonic stem cells (hESCs) (10) and human induced pluripotent stem cells (hiPSCs) (11, 12) were crucial advances in the area of regenerative medicine. Notably, hiPSC-based platelet generation is a particularly fascinating therapy model, in part because blood donors are becoming increasing scarce in most industrial countries, including Japan (13) . In addition, because platelets are anucleate, they can be 4 subjected to gamma irradiation prior to their transfusion, which would prevent the occurrence of oncogenesis or teratoma formation due to the presence of residual undifferentiated hiPSCs or hiPSC-derived cells. Finally, for patients requiring repeated transfusions, it is important that the platelets are human leukocyte antigen (HLA)-matched (13) ; thus an HLA-identical donor could provide the origin cells for creating iPSCs that contribute to a sustained platelet supply.
Here, by primarily using human ESCs as a gold standard of reference (14, 15) , we describe a two-dimensional flow culture that recapitulates bone marrow in the view of "blood flow" application and may be a feasible system for in vitro generation of platelets from human pluripotent stem cell-derived MKs in numbers sufficient for transfusion therapy.
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Methods
Cells and Reagents
The KhES-3 human ESC clone (Institute for Frontier Medical Science, Kyoto University, Kyoto, Japan) was used upon the approval by the Minister of Education, Culture, Sports, Science, and Technology of Japan (MEXT) (14) . In addition, The TkDA3-4 hiPSC clone was used (15) .
The mouse C3H10T1/2 cell line was purchased from the RIKEN Bio-Resource Center (Tsukuba, Ibaraki, Japan) and was cultured as described previously (14, 15) . Human umbilical cord endothelial cells (HUVECs) were purchased from KURABO (Tokyo, Japan). Human vascular endothelial growth factor (VEGF), human thrombopoietin (TPO) and human stem cell factor (SCF) were all from R&D Systems (Minneapolis, MN). Heparin was from Ajinomoto Pharmaceuticals Co., LTD (Tokyo, Japan). The following antibodies and stains were obtained from BD Biosciences (Franklin Lakes, NJ): allophycocyanin (APC)-conjugated anti-CD41a, FITC-conjugated anti-CD41a (GPIX), anti-CD42b (GPIb) and Hoechst 33342 (blue). DAPI (Vector Laboratories, Burlingame, CA) and Hoechst 33342 were used for nuclear staining in MKs. FITC-conjugated PAC-1 antibody (BD Biosciences, San Diego, CA) was used for platelet activation studies as described (14, 15) .
Hematopoietic differentiation of human ESCs or iPSCs
Differentiation of human ESCs or iPSCs into hematopoietic cells was performed as described previously (14, 15) . In brief, small clumps of ESCs or iPSCs (<100 cells treated with PBS containing 0.25% trypsin (Invitrogen, Carlsbad, CA), 1 mM CaCl 2 (Sigma-Aldrich, St. Louis, Life technology Japan, Tokyo] with 15% fetal bovine serum and VEGF as described previously (14, 15) , which was replaced every 3 days. On days 14-15 of culture, the HPCs within ES- (14) or iPS-Sacs (15) were collected, transferred onto fresh mitomycin-treated or irradiated feeder cells, and further cultivated in differentiation medium supplemented with 50 ng/ml TPO, 50 ng/ml SCF and 25 U/ml heparin sodium, as described (14, 15) . The medium was refreshed every 3 days, and non-adherent cells were collected on day 20 of culture and transferred to a bioreactor.
Flow cytometric analysis of platelets
Washed platelets were prepared as described previously (14, 15) . The resultant platelet pellets were resuspended with staining medium and stained with anti-human CD41a-APC and CD42b-PE for 30 min at room temperature. The platelets were then diluted in 200 l of staining medium and analyzed by flow cytometry (FACSAria, BD biosciences, San Diego, CA).
Platelet numbers were counted using True Count Beads (BD Biosciences).
Construction of a bioreactor to obtain platelets from human iPSC-derived MKs
The fabrication of a bioreactor to produce platelets entailed the following steps. Using photo-resist SU8-3050 (Nippon Kayaku, Tokyo, Japan), a microfluidic device was constructed by centrifugation on a silicon wafer at 5000 rpm for 30 s. The device was then exposed after 7 applying a mask using a mask aligner, developed in developer and rinsed with de-ionized water.
Polydimethylpolysiloxane (PDMS) was then solidified on the fabricated mold at 60°C in an oven. Finally, the PDMS was released from the mold and bonded to a glass plate.
Experimental procedure (dissemination of cells, culture and counting platelets)
Sterilization of the bioreactor was achieved through treatment with ethanol for 30 min irradiation with UV light. Platelet generation in the bioreactor was observed in a connected circulation system on the stage of a confocal microscope (FV1000, Olympus, Tokyo, Japan) at 37°C. The process of platelet generation from MKs was visualized using a confocal microscope system, and the images were recorded in the hard disc of a connected computer.
Flow pressure was determined by flow speed and the medium collected, including the cell populations in the reservoir. After adding ACD medium to the culture medium (1:10 dilution), the collected samples were centrifuged at 900 rpm for 10 min (slow acceleration). Finally, the cell samples were stained for cell surface molecules specific for MKs/platelets and analyzed by flow cytometry.
Statistics
We evaluated results by using an unpaired t-test for significance.
Results and Discussion
Observations in living mice made using two-photon confocal microscopy revealed that platelet release occurs within both the capillaries and sinusoids of the bone marrow (8) . Within human bone marrow, sinusoidal capillaries are the discontinuous type, with wall thicknesses less than 30 m and containing numerous pores. One approach to reconstituting the structure of such vessels in vitro is to use a sheet-like scaffold with multiple pores (16) . We constructed a structure using the salt-leaching method as shown in Figure 1A . The contents of the solution used for the salt-leaching are shown in Table 1 .
Using the constructed sheet-like porous structure, we designed the bioreactor to recapitulate mainly two functions of capillary blood vessel for platelet production: (i) one function that is a porous structure of endothelial cells for fixing MKs on the outside of blood vessel wall (17) , and, (ii) another function that is a platelet production of MKs by applying the shearing effects of blood flow. Within the bioreactor, the membrane scaffold for platelet release from MKs was composed of PDMS. Moreover, the scaffold was completely covered by HUVECs where adjacent chamber with a layer of HUVECs and a formed porous barrier in between appeared 30 m. By adjusting the speed of flow through the structure, different levels of shear stress were generated, which were calculated using equation In the system, the medium flows past MKs on HUVECs in two directions (pressure flow and main flow), such that the pressure flow is perpendicular to the main flow; the main flow applies shear stress to the MKs, while the pressure flow applies pressure for MK fixation to the each slit. Thus we estimated that exposed shear stress was occurred from 0.14-37.5 dyne/cm 2 onto MKs within chamber and iPSC-derived MKs were applied into the regions of the pores, as shown in the left panel of Figure 1B , although it is not ruled out that the flow was turbulence.
In addition, we expected that vascular cell adhesion molecule-1 (VCAM-1) on HUVEC might promote platelet release from MKs because of the reports that integrin 41 expression in MKs is crucial for platelet production in vivo in mouse models (reference 18) or that the binding between integrin 41 in MKs and VCAM-1 promoted proplatelets, a hallmark of platelet generation, from cultured MKs in vitro (19).
Our bioreactor system enabled us to visualize real-time changes to MKs during culture.
Time-lapse confocal microscopy revealed that applied iPSC-derived MKs grew on HUVECs within the bioreactor (Figure 2A) , and the numbers of adherent MKs were greater under weak flow conditions (0.14 dyne/cm 2 ) ( Figure 2B ). We applied 1. Figure 2B ) were counted in the absence or presence of flow respectively. When we compared the final yield of platelets between the static culture (no flow) in a conventional culture dish (14) and our new bioreactor system with flow, as shown in Figure   3A , we found that platelet generation from human ESC-derived MKs tended to be better in the flow system ( Figure 3B ). Moreover, time-lapse imaging of the platelet production from MKs under flow revealed that increasing the shear stress by adjusting flow speed (1.0 ml/hr) stimulated large-proplatelet (90 min in Figure 4 ), followed by cytoplasmic fragmentation from ESC-derived MKs (92 min in Figure 4 ). However, the increase in platelet production was not significant ( Figure 3B ).
To improve platelet yield, we designed a new bioreactor using two flows with an angle between the main and pressure flows. The schematic in Figure 5A shows the newer design of a bioreactor, in which the angle between the directions of flow is 60°. The platelets were generated from MKs placed between the slits. We again applied 1.2 x 10 5 MKs for each experiment within a newer bioreactor. Under these conditions, the numbers of platelets produced from human ESCs were as much as 3.6 times higher than in static culture (mean count: 19822 under static vs. 71755 under flow, Figure 5B , from independent 4 experiments, p<0.05). These results using the same improved reactor system were confirmed by using human iPSC-derived MKs (2 experiments, data not shown). Purity of CD41a + or CD42b + platelet populations was also examined by flow cytometer and there was no significant difference between static condition and bioreactor ( Figure 5C and 5D ).
In order to confirm the functionality by collected platelets through second generation of a bioreactor in Figure 5A , agonist-induced integrin activation in platelets was examined. The PAC-1 binding, the activated form of an integrin IIb3 after agonist stimulation showed intact functionality by hESC-or iPSC-derived platelets (Figure 6 ), confirming the similarity to the previous studies obtained under static conditions (14, 15) .
Using a novel 3-dimensional bioreactor, which enabled us to regulate shear stress through application of flow in two directions, we enhanced platelet generation from MKs by subjecting the cells to the appropriate levels of shear stress. Within this system the shear stress created by 11 the main flow could be regulated by the pressure flow. Furthermore, it appears that an angle of 60° between the main and pressure flows is optimal.
This novel conception has the potential to influence a new era of regenerative medicine through the use of hESCs or hiPSCs. In an effort to better understand the underlying molecular mechanisms of platelet release and production from MKs, we are attempting to mimic previously visualized in vivo platelet production (8) , which showed evidence of shear stress dependence. Recently, several groups reported in vitro platelet generation under conditions in which high shear stress was produced utilizing one-directional flow (18, 21). On the other hand, our proposed bioreactor makes use of flow in two directions. We suggest that the flow applying pressure to the cells stimulates MK maturation on HUVECs, while the flow applying shear stress stimulates platelet generation. In addition, it appears that the angle between those two-directional flow a key for improving production efficiency as exemplified by three times difference in comparison between Figures 3 and 5 ). This two-direction flow strategy is seemingly a feasible approach to the future development of bioreactors able to supply platelets derived from human pluripotent stem cells in numbers sufficient for transfusion. drying at room temperature for 2 minutes. The PLCL-coated PVA models then were soaked in deionized (DI) water followed by dissolution of PVA and the NaCl microparticles. After PVA and the NaCl microparticles were completely removed from the PLCL, the salt-leached PLCL scaffold was dried for 24 hours at room temperature.
(B) Culture within the reactor system was performed at 37°C in a CO 2 incubator. Circulation was achieved using a PFA tube connected to a roller pump to produce flow. The left side schematic shows the cross-sectional view of bioreactor. Human umbilical vascular endothelial cells (HUVECs) were pre-applied for stable adhesion to the micropores in the scaffold 2 days before the megakaryocytes (MKs) were applied. 
